ABBV-744 IN COMBINATION WITH IMMUNOTHERAPY - AN OVERVIEW

The current work examined the potential of using ARV-825 and ABBV-744 to raise the effectiveness of tamoxifen or fulvestrant plus palbociclib. ARV-825 was effective in the two p53 wild-style (WT) breast tumor cells As well as in cells missing functional p53 either on your own or in combination with tamoxifen, even though the effectiveness of ABBV-7